4 most recent filings and news items mentioning VXRT. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/VXRT/news?limit=20"
Pull VXRT filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayVaxart stockholders rejected an advisory vote on executive compensation while ratifying auditor selection. The rejection of the say-on-pay proposal highlights investor concerns regarding executive compensation structures.
View filing at SEC.gov →Vaxart reported top-line safety data for its Phase 2b oral COVID-19 vaccine, finding no vaccine-related serious adverse events or sustained Grade 3 adverse events. This positive result supports the oral pill candidate's development profile as efficacy data is still pending.
View filing at SEC.gov →Vaxart and a group of stockholders agreed to a cooperation agreement ending a recent proxy contest. The group has withdrawn its director nominations for the 2026 annual meeting, which is expected to avert potential voting instability.
View filing at SEC.gov →Vaxart received additional BARDA funding to advance COVID-19 vaccine data analysis. The release allows the company to report 12-month trial data.
View filing at SEC.gov →